Brian P. Schmitt, MD | Authors

WALGREENS PHARMACY

1300 FRANKLIN AVE

Port Washington

11050

Articles

Study Results of Maximum Androgen Blockade Not Clearcut

February 01, 1999

Androgen suppression, primarily castration, has been the key objective of treatment of metastatic prostate cancer. Surgical castration, achieved by the use of bilateral orchiectomy, produces a short-term symptomatic and objective tumor response in 70% to 80% of patients.[1] Medical castration, by the use of leuteinizing hormone-releasing hormone (LHRH) agonists, produces an almost equivalent effect. However, use of medical or surgical castration eliminates only 90% to 95% of the daily testosterone production. The remainder is produced in the adrenal glands.